Sanofi (NASDAQ:SNY) Stock Rating Lowered by StockNews.com

Sanofi (NASDAQ:SNY - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Thursday.

Separately, Citigroup raised Sanofi to a "strong-buy" rating in a report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $57.50.

Sanofi Trading Down 2.1 %

NASDAQ SNY traded down $1.00 during mid-day trading on Thursday, reaching $46.99. 2,601,752 shares of the stock were exchanged, compared to its average volume of 2,060,430. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a market cap of $119.25 billion, a P/E ratio of 24.48, a P/E/G ratio of 1.23 and a beta of 0.58. The stock has a 50 day simple moving average of $51.36 and a 200-day simple moving average of $52.09. Sanofi has a one year low of $45.22 and a one year high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analysts' expectations of $16.59 billion. During the same period last year, the company posted $2.55 earnings per share. The business's quarterly revenue was up 12.3% on a year-over-year basis. On average, analysts anticipate that Sanofi will post 4.27 EPS for the current year.

Hedge Funds Weigh In On Sanofi

Institutional investors have recently modified their holdings of the company. Northwest Investment Counselors LLC bought a new stake in Sanofi during the 3rd quarter valued at $29,000. POM Investment Strategies LLC purchased a new stake in shares of Sanofi in the 2nd quarter worth about $25,000. Concord Wealth Partners lifted its position in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company's stock valued at $34,000 after acquiring an additional 363 shares during the period. Arrow Financial Corp bought a new stake in Sanofi during the second quarter worth about $35,000. Finally, Sunbelt Securities Inc. grew its holdings in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock worth $43,000 after purchasing an additional 313 shares during the period. 10.04% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.